InvestorsHub Logo
Followers 62
Posts 7557
Boards Moderated 1
Alias Born 01/02/2003

Re: None

Tuesday, 09/20/2022 1:56:05 PM

Tuesday, September 20, 2022 1:56:05 PM

Post# of 426482
Vascepa's prime competitor is not gV...The prime competitors are Lovaza and DS fish oils(more than twice the market that Vascepa has)...Amarin needs to call out their competitors, in advertisements, explaining why Vascepa is better than the competitors in reducing CVD.

Many people have had a CVD event or have a family member, who has had one...If they were informed of why Vascepa is superior to the competition, they might be willing to pay somewhat more to switch to a drug with more efficacy...and pressure their Docs to give them an Rx for it.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News